These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 31111633)

  • 41. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.
    Anthias C; Dignan FL; Morilla R; Morilla A; Ethell ME; Potter MN; Shaw BE
    Bone Marrow Transplant; 2014 May; 49(5):679-83. PubMed ID: 24510069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease].
    Zhang YM; Zhang Y; Ni X; Gao L; Qiu HY; Zhang YS; Tang GS; Chen J; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):16-22. PubMed ID: 32023749
    [No Abstract]   [Full Text] [Related]  

  • 44. [Allogenic transplantation of hematopoietic stem cells in the treatment of children with high-risk acute leukemia].
    Starý J; Kobylka P; Sedlácek P; Komrska V; Vávra V; Syrůcková Z; Smísek P; Hrubá A; Korínková P; Matĕjková E; Cukrová V; Dolezalová L; Loudová M; Sejkorová J; Kvĕch J
    Cas Lek Cesk; 1998 Jun; 137(12):363-7. PubMed ID: 9721472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China.
    Ding J; Su Y; Ruan Y; Li N; Meng Q; Yang J; Chen L; Liu C
    Hematology; 2024 Dec; 29(1):2310960. PubMed ID: 38323781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center.
    Gassas A; Ishaqi MK; Afzal S; Finkelstein-Shechter T; Dupuis A; Doyle J
    Bone Marrow Transplant; 2008 Jun; 41(11):941-5. PubMed ID: 18264141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
    Núñez-Torrón Stock C; Jiménez Chillón C; Martín Moro F; Marquet Palomanes J; Velázquez Kennedy K; Piris Villaespesa M; Roldán Santiago E; Rodríguez Martín E; Chinea Rodríguez A; García Gutiérrez V; Moreno Jiménez G; López Jiménez J; Herrera Puente P
    Hematol Oncol; 2023 Oct; 41(4):753-761. PubMed ID: 37081742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements.
    Yang H; Huang S; Zhu CY; Gao L; Zhu HY; Lv N; Jing Y; Yu L
    Med Sci Monit; 2016 Jul; 22():2315-23. PubMed ID: 27373985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
    Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
    Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
    Adrianzen Herrera D; Kornblum N; Derman O; Bachier-Rodriguez L; Sica RA; Shastri A; Janakiram M; Verma A; Braunschweig I; Mantzaris I
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
    Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
    J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemopoietic stem cell transplantation in Australia, 1992-95: a report from the Australian Bone Marrow Transplant Recipient Registry.
    Atkinson K; Nivison-Smith I; Hawkins T
    Aust N Z J Med; 1997 Aug; 27(4):408-19. PubMed ID: 9448882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
    Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
    Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
    Guolo F; Di Grazia C; Minetto P; Raiola AM; Clavio M; Miglino M; Tedone E; Contini P; Mangerini R; Kunkl A; Colombo N; Pugliese G; Carminati E; Marcolin R; Passannante M; Bagnasco S; Galaverna F; Lamparelli T; Ballerini F; Cagnetta A; Cea M; Gobbi M; Bacigalupo A; Lemoli RM; Angelucci E
    Eur J Haematol; 2021 Nov; 107(5):573-582. PubMed ID: 34297437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study.
    de Melo Rodrigues AL; Bonfim C; Seber A; Colturato VAR; Zecchin VG; Nichele S; Daudt LE; Fernandes JF; Vieira AK; Darrigo Junior LG; Gomes AA; Arcuri L; Lenzi L; Picharski GL; Ribeiro RC; de Figueiredo BC
    Cell Transplant; 2020; 29():963689720949175. PubMed ID: 32787568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
    Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
    Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.